Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a small-molecule inhibitor with high selectivity for Rho-associated protein kinases ROCK1 (IC₅₀ ≈ 140 nM) and ROCK2 (K_i ≈ 300 nM) (APExBIO, product page). It disrupts Rho-mediated stress fiber formation and modulates the cell cycle transition from G1 to S phase (Liu et al., doi:10.3389/fendo.2020.621944). Y-27632 is widely used to enhance stem cell viability and to suppress tumor invasion and metastasis in vitro and in animal models. The compound demonstrates over 200-fold selectivity against kinases such as PKC, PAK, MLCK, and cAMP-dependent protein kinase. Benchmarks confirm its utility for cytoskeletal, proliferation, and cancer research workflows.

Biological Rationale

The Rho/ROCK pathway regulates cytoskeletal remodeling, cell motility, and cell cycle progression. RhoA activates ROCK1/2, leading to phosphorylation of downstream effectors such as myosin light chain (MLC), promoting actomyosin contraction and stress fiber formation. Dysregulation of this pathway is implicated in cancer cell invasion, metastasis, and abnormal proliferation (Liu et al., doi:10.3389/fendo.2020.621944). Targeted inhibition of ROCK kinases enables precise modulation of these processes for research and potential therapeutic investigation.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a potent, ATP-competitive inhibitor targeting the catalytic domains of ROCK1 and ROCK2. At concentrations as low as 140 nM (IC₅₀ for ROCK1), it blocks kinase activity by preventing ATP binding (APExBIO, product page). This inhibition disrupts phosphorylation of MLC and other substrates, resulting in decreased cellular contractility, loss of stress fibers, and impaired cytokinesis. The compound is highly selective, with >200-fold weaker activity against kinases including PKC, PAK, MLCK, and cAMP-dependent protein kinase, minimizing off-target effects (APExBIO).

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 (IC₅₀ ≈ 140 nM) and ROCK2 (K_i ≈ 300 nM), with >200-fold selectivity over other kinases (APExBIO).
• In breast cancer cell models, ROCK inhibition by Y-27632 reverses QPRT-induced myosin light chain phosphorylation and cell invasion (Liu et al., doi:10.3389/fendo.2020.621944).
• Y-27632 reduces proliferation of prostatic smooth muscle cells in a concentration-dependent manner in vitro (APExBIO).
• In mouse tumor models, Y-27632 diminishes pathological tissue structures and suppresses tumor invasion and metastasis (Liu et al., doi:10.3389/fendo.2020.621944).
• The compound is highly soluble (≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water) and stable at -20°C for several months when stored as a stock solution (APExBIO).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is a benchmark reagent for:

• Dissecting the Rho/ROCK signaling pathway in cell biology.
• Modulating cytoskeletal dynamics and stress fiber formation in various cell types, including epithelial and neuronal cells (see contrast: neuro-epithelial focus; this article emphasizes cancer and general cytoskeletal research).
• Enhancing stem cell viability and clonogenicity during cell culture passaging (see: comprehensive protocols; here, mechanisms and pitfalls are clarified).
• Inhibiting cell migration, invasion, and metastasis in cancer research (contrasts with basic selectivity overview; this article updates with in vivo benchmarks and mechanistic detail).
• Studying cytokinesis, cell proliferation, and the G1/S cell cycle checkpoint.

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit all kinases in the Rho pathway; its selectivity is limited to ROCK1/2 and not upstream GTPases.
• The compound is not cytotoxic at standard working concentrations (≤10 μM), but higher doses or prolonged exposure may affect cell viability due to off-target effects.
• Long-term storage of aqueous stock solutions at room temperature leads to degradation; always store desiccated at ≤4°C or stock solutions at ≤-20°C.
• Y-27632 does not fully prevent metastasis in all tumor models; effects are context-dependent and may require combination with other agents.
• It is not a direct therapeutic for clinical use; it is intended for research applications only.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid and should be stored desiccated at 4°C or below. For experimental use:

• Dissolve in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL). Warming to 37°C or using an ultrasonic bath may enhance solubility.
• Prepare aliquots and store stock solutions at ≤-20°C. Avoid repeated freeze-thaw cycles.
• For in vitro applications, typical working concentrations range from 1 μM to 10 μM, with exposure times from 30 minutes to 72 hours depending on the assay.
• Monitor for precipitation or color change in solutions, indicating possible degradation.
• Refer to the APExBIO product page (A3008 kit) for lot-specific instructions and certificates of analysis.

Conclusion & Outlook

Y-27632 dihydrochloride is a validated, selective ROCK inhibitor used for precise modulation of Rho/ROCK signaling in cell biology and cancer research. Its potency, solubility, and selectivity profile make it a gold standard reagent for cytoskeletal, stem cell, and anti-invasion studies. As research advances, Y-27632 will continue to underpin experimental approaches dissecting cytoskeletal regulation, cell proliferation, and metastatic mechanisms. For further protocol optimization and advanced troubleshooting, consult comparative resources and emerging literature. For comprehensive product specifications, visit the APExBIO Y-27632 dihydrochloride page.